Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial.

[1]  C. Sprung,et al.  Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 , 2021, Intensive Care Medicine.

[2]  A. Mebazaa,et al.  sTREM-1 is a specific biomarker of TREM-1 pathway activation , 2021, Cellular & Molecular Immunology.

[3]  A. Olivier,et al.  Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial , 2021, BMJ Open.

[4]  F. Vandenhende,et al.  Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial , 2020, Intensive Care Medicine.

[5]  M. Levy,et al.  The SOFA score—development, utility and challenges of accurate assessment in clinical trials , 2019, Critical Care.

[6]  G. Martin,et al.  Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial. , 2019, JAMA.

[7]  A. Mebazaa,et al.  Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study , 2018, Critical Care.

[8]  A. Olivier,et al.  A first‐in‐man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM‐1 receptor inhibition , 2018, British journal of clinical pharmacology.

[9]  M. Weigand,et al.  Soluble TREM-1 as a diagnostic and prognostic biomarker in patients with septic shock: an observational clinical study , 2017, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[10]  R. Bellomo,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[11]  Christopher W Seymour,et al.  Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[12]  S. Opal,et al.  Sepsis: a roadmap for future research. , 2015, The Lancet. Infectious diseases.

[13]  S. Opal,et al.  The Next Generation of Sepsis Clinical Trial Designs: What Is Next After the Demise of Recombinant Human Activated Protein C?* , 2014, Critical care medicine.

[14]  S. Gibot,et al.  Attenuation of Responses to Endotoxin by the Triggering Receptor Expressed on Myeloid Cells-1 Inhibitor LR12 in Nonhuman Primate , 2014, Anesthesiology.

[15]  P. Leroy,et al.  Effects of a TREM-Like Transcript 1–Derived Peptide During Hypodynamic Septic Shock in Pigs , 2013, Shock.

[16]  F. Massin,et al.  Soluble Trem-like Transcript-1 Regulates Leukocyte Activation and Controls Microbial Sepsis , 2012, The Journal of Immunology.

[17]  Derek C Angus,et al.  The search for effective therapy for sepsis: back to the drawing board? , 2011, JAMA.

[18]  John D. Storey,et al.  A genomic storm in critically injured humans , 2011, The Journal of experimental medicine.

[19]  R. D. Meyer,et al.  Covariate-Adjusted Difference in Proportions from Clinical Trials Using Logistic Regression and Weighted Risk Differences , 2011 .

[20]  S. Gibot.  Clinical review: Role of triggering receptor expressed on myeloid cells-1 during sepsis , 2005, Critical care.

[21]  M. Colonna,et al.  TREM-1 amplifies inflammation and is a crucial mediator of septic shock , 2001, Nature.

[22]  M. Colonna,et al.  Cutting Edge: Inflammatory Responses Can Be Triggered by TREM-1, a Novel Receptor Expressed on Neutrophils and Monocytes1 , 2000, The Journal of Immunology.

[23]  C. Summers,et al.  Bridging the Translational Gap: The Challenges of Novel Drug Development in Critical Care , 2017 .